| A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence GM Conenello, D Zamarin, LA Perrone, T Tumpey, P Palese PLoS Pathog 3 (10), e141, 2007 | 544 | 2007 |
| Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy D Zamarin, RB Holmgaard, SK Subudhi, JS Park, M Mansour, P Palese, ... Science translational medicine 6 (226), 226ra32-226ra32, 2014 | 525 | 2014 |
| Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 RB Holmgaard, D Zamarin, DH Munn, JD Wolchok, JP Allison Journal of Experimental Medicine 210 (7), 1389-1402, 2013 | 480 | 2013 |
| A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity L Glaser, J Stevens, D Zamarin, IA Wilson, A García-Sastre, TM Tumpey, ... Journal of virology 79 (17), 11533-11536, 2005 | 464 | 2005 |
| Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1 D Zamarin, A García-Sastre, X Xiao, R Wang, P Palese PLoS pathogens 1 (1), e4, 2005 | 448 | 2005 |
| Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice D Zamarin, MB Ortigoza, P Palese Journal of virology 80 (16), 7976-7983, 2006 | 375 | 2006 |
| Attenuation of equine influenza viruses through truncations of the NS1 protein M Quinlivan, D Zamarin, A García-Sastre, A Cullinane, T Chambers, ... Journal of virology 79 (13), 8431-8439, 2005 | 265 | 2005 |
| Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner RB Holmgaard, D Zamarin, Y Li, B Gasmi, DH Munn, JP Allison, ... Cell reports 13 (2), 412-424, 2015 | 255 | 2015 |
| Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient A Jiménez-Sánchez, D Memon, S Pourpe, H Veeraraghavan, Y Li, ... Cell 170 (5), 927-938. e20, 2017 | 242 | 2017 |
| TOX is a critical regulator of tumour-specific T cell differentiation AC Scott, F Dündar, P Zumbo, SS Chandran, CA Klebanoff, M Shakiba, ... Nature 571 (7764), 270-274, 2019 | 208 | 2019 |
| Nuclear localization of the Nipah virus W protein allows for inhibition of both virus-and toll-like receptor 3-triggered signaling pathways ML Shaw, WB Cardenas, D Zamarin, P Palese, CF Basler Journal of virology 79 (10), 6078-6088, 2005 | 190 | 2005 |
| Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions D Zamarin, P Palese Future microbiology 7 (3), 347-367, 2012 | 183 | 2012 |
| Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells M Mansour, P Palese, D Zamarin Journal of virology 85 (12), 6015-6023, 2011 | 130 | 2011 |
| Consensus guidelines for the definition, detection and interpretation of immunogenic cell death L Galluzzi, I Vitale, S Warren, S Adjemian, P Agostinis, AB Martinez, ... Journal for immunotherapy of cancer 8 (1), 2020 | 100 | 2020 |
| Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses D Zamarin, L Martínez-Sobrido, K Kelly, M Mansour, G Sheng, A Vigil, ... Molecular Therapy 17 (4), 697-706, 2009 | 99 | 2009 |
| Differential IL-10R1 expression plays a critical role in IL-10-mediated immune regulation Y Ding, L Qin, D Zamarin, SV Kotenko, S Pestka, KW Moore, JS Bromberg The Journal of Immunology 167 (12), 6884-6892, 2001 | 95 | 2001 |
| IRE1α–XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity M Song, TA Sandoval, CS Chae, S Chopra, C Tan, MR Rutkowski, ... Nature 562 (7727), 423-428, 2018 | 94 | 2018 |
| Immune checkpoint modulation: rational design of combination strategies D Zamarin, MA Postow Pharmacology & therapeutics 150, 23-32, 2015 | 84 | 2015 |
| Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity D Zamarin, RB Holmgaard, J Ricca, T Plitt, P Palese, P Sharma, ... Nature communications 8 (1), 1-14, 2017 | 83 | 2017 |
| Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2, 3-dioxygenase … RB Holmgaard, D Zamarin, A Lesokhin, T Merghoub, JD Wolchok EBioMedicine 6, 50-58, 2016 | 83 | 2016 |
Jedd WolchokChief, Melanoma and Immunotherapeutics, MSKCCVerified email at mskcc.org
